Business
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Faeth acquisition adds PIKTOR, an all-oral combination product candidate targeting multiple nodes of the PI3K/AKT/mTOR pathway $200 million private placement
About this update from Sensei Biotherapeutics, Inc.
[{"type":"text","content":"\nFaeth acquisition adds PIKTOR, an all-oral combination product candidate targeting multiple nodes of the PI3K/AKT/mTOR pathway\n\n\n$200 million private placement supports key clinical milestones in endometrial and breast cancer\n\n\n BOSTON--(BUSINESS WIRE)--\nSensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the full year ended December 31, 2025, following its previously announced acquisition of Faeth Therapeutics and concurrent $200 million private placement. The financing, together with the Company's cash on hand, is expected to support advancement of PIKTOR through key clinical milestones, including topline data readouts from both the ongoing Phase 2 trial in advanced endometrial cancer (Study FTH-PIK-201) and the planned Phase 1b trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101).\n\n\nAcquired through the Faeth transaction, PIKTOR is now Sensei’s lead program. The investigational, proprietary, all-oral combination of serabelisib and sapanisertib is designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting.\n\n\n“2025 was a year of focus and discipline for Sensei, and with the addition of Faeth and injection of new capital, we are entering 2026 with a clear path forward,” said Christopher Gerry, President & General Counsel of Sensei Biotherapeutics. “We are now focused on advancing PIKTOR through key clinical milestones, including topline data from the ongoing Phase 2 trial in advanced endometrial cancer and initiation of the planned Phase 1b trial in HR+/HER2- advanced breast cancer, both expected by year-end 2026.”\n\n\n“The data to date suggest PIKTOR may achieve more comprehensive pathway suppression than single-node approaches, with an emerging tolerability profile that compares favorably to existing therapies, highlighting its potential to address significant unmet need in multiple solid tumor indications,” said Anand Parikh, Chief Operating Officer of Sensei Biotherapeutics. “We are focused on disciplined execution as we advance PIKTOR through clinical trials in endometrial and breast cancer, with additional opportunities in ovarian and lung cancer.”\n\n\nFull Year 2025 Financial Results\n\n\nCash Position: Cash, cash equivalents and marketable securities were $21.2 million as of December 31, 2025 as compared to $41.3 mi...